Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Publikationen

Suchbegriffe: DRUG RESISTANCE, NEOPLASM - GENETICS , . Treffer: 20

2017

Račkauskas, R; Zhou, D; Ūselis, S; Strupas, K; Herr, I; Schemmer, P Sulforaphane sensitizes human cholangiocarcinoma to cisplatin via the downregulation of anti-apoptotic proteins.
Oncol Rep. 2017; 37(6):3660-3666 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Smolle, MA; Bauernhofer, T; Pummer, K; Calin, GA; Pichler, M Current Insights into Long Non-Coding RNAs (LncRNAs) in Prostate Cancer.
Int J Mol Sci. 2017; 18(2): [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2016

Bonin, S; Donada, M; Bussolati, G; Nardon, E; Annaratone, L; Pichler, M; Chiaravalli, AM; Capella, C; Hoefler, G; Stanta, G A synonymous EGFR polymorphism predicting responsiveness to anti-EGFR therapy in metastatic colorectal cancer patients.
Tumour Biol. 2016; 37(6):7295-7303
Web of Science PubMed FullText FullText_MUG

 

Fan, P; Liu, L; Yin, Y; Zhao, Z; Zhang, Y; Amponsah, PS; Xiao, X; Bauer, N; Abukiwan, A; Nwaeburu, CC; Gladkich, J; Gao, C; Schemmer, P; Gross, W; Herr, I MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer.
Cancer Lett. 2016; 373(1):130-137
Web of Science PubMed FullText FullText_MUG

 

Jagadeeshan, S; Subramanian, A; Tentu, S; Beesetti, S; Singhal, M; Raghavan, S; Surabhi, RP; Mavuluri, J; Bhoopalan, H; Biswal, J; Pitani, RS; Chidambaram, S; Sundaram, S; Malathi, R; Jeyaraman, J; Nair, AS; Venkatraman, G; Rayala, SK P21-activated kinase 1 (Pak1) signaling influences therapeutic outcome in pancreatic cancer.
Ann Oncol. 2016; 27(8):1546-1556
Web of Science PubMed FullText FullText_MUG

 

Pehserl, AM; Ress, AL; Stanzer, S; Resel, M; Karbiener, M; Stadelmeyer, E; Stiegelbauer, V; Gerger, A; Mayr, C; Scheideler, M; Hutterer, GC; Bauernhofer, T; Kiesslich, T; Pichler, M Comprehensive Analysis of miRNome Alterations in Response to Sorafenib Treatment in Colorectal Cancer Cells.
Int J Mol Sci. 2016; 17(12): [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Perakis, SO; Thomas, JE; Pichler, M Non-coding RNAs Enabling Prognostic Stratification and Prediction of Therapeutic Response in Colorectal Cancer Patients.
Adv Exp Med Biol. 2016; 937(4):183-204
Web of Science PubMed FullText FullText_MUG

 

Verbrugge, SE; Al, M; Assaraf, YG; Kammerer, S; Chandrupatla, DM; Honeywell, R; Musters, RP; Giovannetti, E; O'Toole, T; Scheffer, GL; Krige, D; de Gruijl, TD; Niessen, HW; Lems, WF; Kramer, PA; Scheper, RJ; Cloos, J; Ossenkoppele, GJ; Peters, GJ; Jansen, G Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival activation ERK/Akt/mTOR.
Oncotarget. 2016; 7(5):5240-5257 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Zebisch, A; Hatzl, S; Pichler, M; Wölfler, A; Sill, H Therapeutic Resistance in Acute Myeloid Leukemia: The Role of Non-Coding RNAs.
Int J Mol Sci. 2016; 17(12): [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2015

Fisser, MC; Rommer, A; Steinleitner, K; Heller, G; Herbst, F; Wiese, M; Glimm, H; Sill, H; Wieser, R Induction of the proapoptotic tumor suppressor gene Cell Adhesion Molecule 1 by chemotherapeutic agents is repressed in therapy resistant acute myeloid leukemia.
Mol Carcinog. 2015; 54(12):1815-1819 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Thomas, J; Ohtsuka, M; Pichler, M; Ling, H MicroRNAs: Clinical Relevance in Colorectal Cancer.
Int J Mol Sci. 2015; 16(12):28063-28076 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2014

Fröhlich, LF; Mrakovcic, M; Smole, C; Lahiri, P; Zatloukal, K Epigenetic silencing of apoptosis-inducing gene expression can be efficiently overcome by combined SAHA and TRAIL treatment in uterine sarcoma cells.
PLoS One. 2014; 9(3):e91558-e91558 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Kolb, D; Pritz, E; Steinecker-Frohnwieser, B; Lohberger, B; Deutsch, A; Kroneis, T; El-Heliebi, A; Dohr, G; Meditz, K; Wagner, K; Koefeler, H; Leitinger, G; Leithner, A; Liegl-Atzwanger, B; Zweytick, D; Rinner, B Extended ultrastructural characterization of chordoma cells: the link to new therapeutic options.
PLoS One. 2014; 9(12):e114251-e114251 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Mohan, S; Heitzer, E; Ulz, P; Lafer, I; Lax, S; Auer, M; Pichler, M; Gerger, A; Eisner, F; Hoefler, G; Bauernhofer, T; Geigl, JB; Speicher, MR Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing.
PLoS Genet. 2014; 10(3):e1004271-e1004271 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2012

Pichler, M; Winter, E; Stotz, M; Eberhard, K; Samonigg, H; Lax, S; Hoefler, G; Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer.
Br J Cancer. 2012; 106(11):1826-1832 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Szkandera, J; Absenger, G; Dandachi, N; Regitnig, P; Lax, S; Stotz, M; Samonigg, H; Renner, W; Gerger, A Analysis of functional germline polymorphisms for prediction of response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Mol Genet Genomics. 2012; 287(9):755-764
Web of Science PubMed FullText FullText_MUG

 

2010

Terheyden, P; Houben, R; Pajouh, P; Thorns, C; Zillikens, D; Becker, JC Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene.
J Invest Dermatol. 2010; 130(1):314-316 (- Case Report) [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2007

Miething, C; Grundler, R; Mugler, C; Brero, S; Hoepfl, J; Geigl, J; Speicher, MR; Ottmann, O; Peschel, C; Duyster, J Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment.
Proc Natl Acad Sci U S A. 2007; 104(11): 4594-4599. [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG Google Scholar

 

Wobser, M; Voigt, H; Eggert, AO; Houben, R; Kauczok, CS; Brocker, EB; Becker, JC Bcl-2 expression in rituximab refractory cutaneous B-cell lymphoma.
Br J Cancer. 2007; 96(10):1540-1543 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG Google Scholar

 

2006

Olaussen, KA; Dunant, A; Fouret, P; Brambilla, E; André, F; Haddad, V; Taranchon, E; Filipits, M; Pirker, R; Popper, HH; Stahel, R; Sabatier, L; Pignon, JP; Tursz, T; Le Chevalier, T; Soria, JC; IALT Bio Investigators DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.
N ENGL J MED. 2006; 355: 983-991. [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

© Med Uni Graz Impressum